Tricyclic kinase inhibitors and uses thereof
AssigneeDana-Farber Cancer Institute, Inc.
InventorsNathanael S. Gray, Tinghu Zhang, Yao Liu, David Weinstock, Loretta Sze-Mun Li
Life of this patent
Estimating the term…
Loading patent…
AssigneeDana-Farber Cancer Institute, Inc.
InventorsNathanael S. Gray, Tinghu Zhang, Yao Liu, David Weinstock, Loretta Sze-Mun Li
Estimating the term…
The present disclosure provides compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., Janus kinase (JAK) (e.g., Janus kinase 2 (JAK2)) and/or cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 11 (CDK11)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating a disease (e.g., proliferative disease) in a subject in need thereof).
A compound of Formula (I) or (II):
Dependencies are inferred from the claim text.